Abstract
Abnormal tumour vasculature has a significant impact on tumour progression and response to therapy. Nitric oxide (NO) regulates angiogenesis and maintains vascular homeostasis and, thus, can be delivered to normalize tumour vasculature. However, a NO-delivery system with a prolonged half-life and a sustained release mechanism is currently lacking. Here we report the development of NanoNO, a nanoscale carrier that enables sustained NO release to efficiently deliver NO into hepatocellular carcinoma. Low-dose NanoNO normalizes tumour vessels and improves the delivery and effectiveness of chemotherapeutics and tumour necrosis factor-related, apoptosis-inducing, ligand-based therapy in both primary tumours and metastases. Furthermore, low-dose NanoNO reprogrammes the immunosuppressive tumour microenvironment toward an immunostimulatory phenotype, thereby improving the efficacy of cancer vaccine immunotherapy. Our findings demonstrate the ability of nanoscale NO delivery to efficiently reprogramme tumour vasculature and immune microenvironments to overcome resistance to cancer therapy, resulting in a therapeutic benefit.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
The data supporting the findings of this study are available within the paper and its Supplementary Information. All relevant data are available from the authors upon reasonable request.
References
Jain, R. K., Munn, L. L. & Fukumura, D. Dissecting tumour pathophysiology using intravital microscopy. Nat. Rev. Cancer 2, 266–276 (2002).
Fukumura, D. & Jain, R. K. Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J. Cell Biochem. 101, 937–949 (2007).
Schaaf, M. B., Garg, A. D. & Agostinis, P. Defining the role of the tumor vasculature in antitumor immunity and immunotherapy. Cell Death Dis. 9, 115 (2018).
Gilkes, D. M., Semenza, G. L. & Wirtz, D. Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat. Rev. Cancer 14, 430–439 (2014).
Tredan, O., Galmarini, C. M., Patel, K. & Tannock, I. F. Drug resistance and the solid tumor microenvironment. J. Natl Cancer Inst. 99, 1441–1454 (2007).
Jain, R. K. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J. Clin. Oncol. 31, 2205–2218 (2013).
Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58–62 (2005).
Carmeliet, P. & Jain, R. K. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat. Rev. Drug Discov. 10, 417–427 (2011).
Huang, Y., Stylianopoulos, T., Duda, D. G., Fukumura, D. & Jain, R. K. Benefits of vascular normalization are dose and time dependent—letter. Cancer Res. 73, 7144–7146 (2013).
Huang, Z., Fu, J. & Zhang, Y. Nitric oxide donor-based cancer therapy: advances and prospects. J. Med. Chem. 60, 7617–7635 (2017).
Cheng, H. et al. Nitric oxide in cancer metastasis. Cancer Lett. 353, 1–7 (2014).
Fukumura, D., Kashiwagi, S. & Jain, R. K. The role of nitric oxide in tumour progression. Nat. Rev. Cancer 6, 521–534 (2006).
Wu, S. C. et al. Water-soluble dinitrosyl iron complex (DNIC): a nitric oxide vehicle triggering cancer cell death via apoptosis. Inorg. Chem. 55, 9383–9392 (2016).
Kashiwagi, S. et al. NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels. J. Clin. Invest. 115, 1816–1827 (2005).
Kashiwagi, S. et al. Perivascular nitric oxide gradients normalize tumor vasculature. Nat. Med. 14, 255–257 (2008).
Zhu, A. X., Duda, D. G., Sahani, D. V. & Jain, R. K. HCC and angiogenesis: possible targets and future directions. Nat. Rev. Clin. Oncol. 8, 292–301 (2011).
Llovet, J. M. et al. Hepatocellular carcinoma. Nat. Rev. Dis. Primers 2, 16018 (2016).
Reiberger, T. et al. An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis. Nat. Protoc. 10, 1264–1274 (2015).
Powell, J. A., Mohamed, S. N., Kerr, J. S. & Mousa, S. A. Antiangiogenesis efficacy of nitric oxide donors. J. Cell Biochem. 80, 104–114 (2000).
Ziche, M. & Morbidelli, L. Nitric oxide and angiogenesis. J. Neurooncol. 50, 139–148 (2000).
Chauhan, V. P. et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat. Nanotechnol. 7, 383–388 (2012).
Stylianopoulos, T., Munn, L. L. & Jain, R. K. Reengineering the tumor vasculature: improving drug delivery and efficacy. Trends Cancer 4, 258–259 (2018).
Wahl, K. et al. Increased apoptosis induction in hepatocellular carcinoma by a novel tumor-targeted TRAIL fusion protein combined with bortezomib. Hepatology 57, 625–636 (2013).
von Karstedt, S., Montinaro, A. & Walczak, H. Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy. Nat. Rev. Cancer 17, 352–366 (2017).
Liu, C. H. et al. A multifunctional nanocarrier for efficient TRAIL-based gene therapy against hepatocellular carcinoma with desmoplasia in mice. Hepatology 67, 899–913 (2018).
Huang, Y., Goel, S., Duda, D. G., Fukumura, D. & Jain, R. K. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res. 73, 2943–2948 (2013).
Huang, Y., Snuderl, M. & Jain, R. K. Polarization of tumor-associated macrophages: a novel strategy for vascular normalization and antitumor immunity. Cancer Cell 19, 1–2 (2011).
Peterson, T. E. et al. Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. Proc. Natl Acad. Sci. USA 113, 4470–4475 (2016).
Kloepper, J. et al. Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Proc. Natl Acad. Sci. USA 113, 4476–4481 (2016).
Jiang, Y., Li, Y. & Zhu, B. T-cell exhaustion in the tumor microenvironment. Cell Death Dis. 6, e1792 (2015).
Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350–1355 (2018).
Calderaro, J. et al. Programmed death ligand 1 expression in hepatocellular carcinoma: relationship with clinical and pathological features. Hepatology 64, 2038–2046 (2016).
Chen, L. & Han, X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J. Clin. Invest. 125, 3384–3391 (2015).
Sun, C., Mezzadra, R. & Schumacher, T. N. Regulation and function of the PD-L1 checkpoint. Immunity 48, 434–452 (2018).
Tao, L. H. et al. A polymorphism in the promoter region of PD-L1 serves as a binding-site for SP1 and is associated with PD-L1 overexpression and increased occurrence of gastric cancer. Cancer Immunol. Immunother. 66, 309–318 (2017).
Lin, C. C. et al. The efficacy of a novel vaccine approach using tumor cells that ectopically express a codon-optimized murine GM-CSF in a murine tumor model. Vaccine 34, 134–141 (2016).
Yu, T. W., Chueh, H. Y., Tsai, C. C., Lin, C. T. & Qiu, J. T. Novel GM-CSF-based vaccines: one small step in GM-CSF gene optimization, one giant leap for human vaccines. Hum. Vaccin. Immunother. 12, 3020–3028 (2016).
Lu, T. T. et al. Anionic Roussin's red esters (RREs) syn-/anti-[Fe(mu-SEt)(NO)2]2(-): the critical role of thiolate ligands in regulating the transformation of RREs into dinitrosyl iron complexes and the anionic RREs. Inorg. Chem. 47, 6040–6050 (2008)..
Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401–404 (2012).
Chen, Y. et al. Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice. Hepatology 59, 1435–1447 (2014).
Ueno, T., Suzuki, Y., Fujii, S., Vanin, A. F. & Yoshimura, T. In vivo distribution and behavior of paramagnetic dinitrosyl dithiolato iron complex in the abdomen of mouse. Free Radic. Res. 31, 525–534 (1999).
Kim, S. H. et al. Death induction by recombinant native TRAIL and its prevention by a caspase 9 inhibitor in primary human esophageal epithelial cells. J. Biol. Chem. 279, 40044–40052 (2004).
Schaub, F. X. et al. Fluorophore-NanoLuc BRET reporters enable sensitive in vivo optical imaging and flow cytometry for monitoring tumorigenesis. Cancer Res. 75, 5023–5033 (2015).
Campeau, E. et al. A versatile viral system for expression and depletion of proteins in mammalian cells. PLoS ONE 4, e6529 (2009).
Acknowledgements
This study was supported by the Ministry of Science and Technology (nos. 104-2628-B-007-001-MY3, 105-2628-E-007-007-MY3, 108-2321-B-009-004 and 108-2221-E-007-104-MY5 to Y.C. and 103-2632-M-033-001-MY3, 104-2113-M-033-005-MY2, 106-2113-M-007-028-MY2 and 106-2113-M-033-009-MY2 to T.-T.L.); by the Chang Gung Memorial Hospital-National Tsinghua University Joint Research Grant (no. 108Q2508E1); by the National Health Research Institutes (no. NHRI-EX108-10609BC); by the ‘Frontier Research Center on Fundamental and Applied Sciences of Matters’ from the Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (no. 108QR001I5); and by the Ministry of Science and Technology (no. 108-3017-F-007-003). We are also grateful to H.-Y. Tang at College of Biomedical Science and Engineering Center, NTHU for assistance with flow cytometry and confocal laser microscopy and to C.-Y.S. Lai for assistance with pharmacokinetics analysis. We thank the National Laboratory Animal Center, NARLabs, Taiwan for technical support with measurement of blood pressure in mice. We acknowledge Prof. C.-H. Hung, W.-M. Ching, and K.-J. Hsing at the Institute of Chemistry, Academia Sinica and Instrumentation Center, National Taiwan Normal University for EPR measurements.
Author information
Authors and Affiliations
Contributions
Y.-C.S. and Y.C. conceived and designed the experiments and analysed the data. Y.-C.S., P.-R.J., F.-F.H., L.-A.C., C.-C.C., D.-Y.G., J.T.Q., C.-C.L., Y.-S.C., Y.-C.H., J.W., F.-N.W., P.-L.Y., T.-T.L. and Y.C. performed the experiments. F.-F.H., M.-R.W., S.-J.C., J.T.Q., C.-C.L., Y.-S.C., A.-S.C., A.Y-.T.W., J.J.-S.K., C.P.-K.L. and T.-T.L. contributed materials and analysis tools. Y.-C.S., T.-T.L. and Y.C. co-wrote the paper. All authors discussed the results and commented on the manuscript.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Supplementary Information
Supplementary Tables 1–6 and Figs. 1–16.
Rights and permissions
About this article
Cite this article
Sung, YC., Jin, PR., Chu, LA. et al. Delivery of nitric oxide with a nanocarrier promotes tumour vessel normalization and potentiates anti-cancer therapies. Nat. Nanotechnol. 14, 1160–1169 (2019). https://doi.org/10.1038/s41565-019-0570-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41565-019-0570-3
This article is cited by
-
Tumor microenvironment reprogramming combined with immunogenic enhancement by nanoemulsions potentiates immunotherapy
Journal of Nanobiotechnology (2024)
-
Copper-induced injectable hydrogel with nitric oxide for enhanced immunotherapy by amplifying immunogenic cell death and regulating cancer associated fibroblasts
Biomaterials Research (2023)
-
Functionalized MoS2-nanosheets with NIR-Triggered nitric oxide delivery and photothermal activities for synergistic antibacterial and regeneration-promoting therapy
Journal of Nanobiotechnology (2023)
-
Repurposing nitric oxide donating drugs in cancer therapy through immune modulation
Journal of Experimental & Clinical Cancer Research (2023)
-
Ultrasound targeted microbubble destruction-triggered nitric oxide release via nanoscale ultrasound contrast agent for sensitizing chemoimmunotherapy
Journal of Nanobiotechnology (2023)